For research use only. Not for use in humans.

Ralpancizumab (Anti-PCSK9)

Synonyms: PF-05335810 Cat.No.A3022

Ralpancizumab (Anti-PCSK9) is a monoclonal antibody targeting selective proprotein convertase subtilisin kexin 9 (PCSK9). It has the potential in hemorrhagic stroke, hypercholesterolemic, dyslipidemia treatment. MW 145.28 KD.

Ralpancizumab (Anti-PCSK9)

Quality Control

Specificity

Name	Citation	PCSK9
PF-06446846	0	+++
PF-06446846 hydrochloride	0	✔
SBC-110736	0	✔
R-IMPP	0	✔
SBC-115076	9	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Ralpancizumab (Anti-PCSK9) is a monoclonal antibody targeting selective proprotein convertase subtilisin kexin 9 (PCSK9). It has the potential in hemorrhagic stroke, hypercholesterolemic, dyslipidemia treatment. MW 145.28 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/27860267/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1407495-04-8
Isotype	Human IgG2SA
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.